Alto Neuroscience focuses on developing innovative therapies for mental health conditions by leveraging advanced neuroscience and pharmacology. The company employs a precision medicine approach, utilizing biomarker-driven strategies to tailor treatments to individual patients. This methodology aims to enhance the efficacy and safety of their therapeutic offerings, which include novel compounds designed to target specific neurobiological pathways associated with various mental health disorders.

The technologies utilized by Alto Neuroscience encompass a range of drug development processes, including the use of artificial intelligence and machine learning to analyze complex data sets. This enables the identification of potential drug candidates and the optimization of clinical trial designs. Additionally, the company emphasizes the importance of understanding the underlying mechanisms of action for their therapies, ensuring that their products are not only effective but also grounded in robust scientific research.

United States

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

Nervous System Diseases

Psychological Diseases

Alto Neuroscience

Cognitive Impairment Associated with Schizophrenia

 ALTO-101

Major depressive disorder

ALTO-203

ALTO-100

ALTO-300

Depression

Post-traumatic stress disorder

Biologics

Gene Therapy

ALTO-202

Neurodegenerative disease

Neuropsychiatric

ALTO-101

California - North

California

Artificial Intelligence

Small Molecule Pharmaceuticals

Diagnostics

Therapeutic

Alto Neuroscience

Company Details